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Triple-negative breast cancers (TNBCs) are an aggressive breast cancer subtype 
with systemic chemotherapy as the only current treatment option. Metabolic 
reprogramming is key to tumor resistance to stressors including therapy. We 
hypothesized that targeting nutrient-sensing pathways through IGF-1R/IR and mTORC1 
inhibition would increase efficacy of the platinum-based agent carboplatin and that 
autophagy underpins cell survival. We investigated combinatorial drug treatment effects 
on cytotoxicity, target inhibition, and mitochondrial function in MDA-MD-231 cells. IGF-
1R/IR and mTORC1 inhibition with BMS-754807 and everolimus, respectively, 
increased the cytotoxicity of carboplatin while BMS-754807 interacted with the 
autophagy inhibitor chloroquine increasing growth inhibition. This work indicates that 
IGF-1R/IR and/or mTORC1 suppression is potentially synergistic with carboplatin in 
TNBC cells and suggests IGF-1R/IR inhibition can collaborate with autophagy inhibition 
to suppress TNBC growth. We conclude that inhibiting nutrient-sensing metabolic 
pathways with chemotherapy and/or autophagy inhibition warrants additional study as a 
strategy to improve response in women with TNBC.
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CHAPTER 1: INTRODUCTION 
 
Triple Negative Breast Cancer Overview 
 
In the United States, breast cancer (BC) is the most commonly diagnosed cancer 
and second leading cause of cancer death among women, with over 280,000 projected 
cases in 20211. Approximately 30% of women with BC will develop metastases resulting 
in a 5-year relative survival rate of approximately 25% and a median overall survival 
period of approximately 24 months2. An aggressive breast cancer subtype, triple-
negative breast cancer (TNBC), accounts for 10-20% of invasive BC cases and is 
defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and 
human epidermal growth factor receptor 2 (HER-2)3. TNBC occurs more frequently in 
premenopausal young women under 40 years old and notably, incidence is 
disproportionately higher in Black women compared to White women4,5. Compared with 
other molecular BC subtypes, TNBC has a 40% mortality rate within the first five years 
of diagnosis and approximately 46% of patients with TNBC will develop distant 
metastasis, after which the median survival time is only 13.3 months4. Furthermore, the 
rate of relapse in patients with TNBC is 19-40 months compared to 35-67 months in 
patients with non-TNBC4. 
Because TNBC lacks ER, PR, and HER-2, there is a lack of targeted therapies 
available to patients, leaving chemotherapy as the standard approach for TNBC 
treatment, regardless of cancer stage6,7. Chemotherapeutic compounds include taxanes 
which prematurely stop mitosis and ultimately inhibit cell division, anthracyclines that
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are derived from streptomyces bacterium and promote apoptosis, and 
cyclophosphamides that are alkylating agents that produce nitrogen mustard and have 
cytotoxic effects on tumor cells4. Growing evidence of TNBC’s sensitivity to DNA-
damaging agents has increased interest in the use of platinum-based compounds such 
as carboplatin or cisplatin that bind to DNA and induce double-stranded breaks7. These 
breaks ultimately damage DNA, inhibiting its replication and transcription, thereby 
inducing cell death7. However, a major clinical challenge is the development of 
resistance mechanisms in platinum-based chemotherapy treatment8. Though TNBC is 
often more sensitive to neoadjuvant chemotherapy compared to other subtypes, there is 
worse overall survival in patients with residual disease after neoadjuvant therapy.9 As 
chemotherapy remains the standard-of-care treatment for TNBC patients regardless of 
BC stage, alternative strategies are urgently needed to target TNBC progression. 
Signaling Mechanisms 
 
The profound heterogeneity within TNBC complicates identification of specific 
oncogene drivers to develop targeted therapies against TNBC7. However, one potential 
target for treating TNBC is the phosphatidylinositol 3-kinase/RAC-alpha 
serine/threonine-protein kinase/mammalian target of rapamycin (PI3K/AKT/mTOR) 
cascade which plays a critical role in cell proliferation, survival, and metabolism and is 
frequently dysregulated in TNBC (Fig. 1)10. The stimulation of receptor tyrosine kinases 
such as insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF-1R) triggers 
phosphorylation of insulin receptor substrate (IRS) proteins11. Furthermore, IGF-1/IGF-
1R binding activates PI3K to produce lipid messengers that activate the AKT cascade 




 Insulin-like growth factor (IGF) is a family of growth hormones that play a crucial 
role in normal human growth and development. The IGF family is composed of IGF-1 
and IGF- 2, which bind to receptors IGF-1R and IGF-2R to activate various intracellular 
signaling cascades involved in cell proliferation, differentiation, and apoptosis12,13. 
Though its role in cancer progression has not been fully elucidated, IGF-1 signaling has 
been extensively implicated in cancer development and progression12. Specifically, IGF-
1R plays a well-known role in anchorage-independent growth, a defining characteristic 
of malignant cancer cells14.  In many cases of BC, IGF-1R levels are increased 
regardless of BC subtype15. Furthermore, greater than 50% of breast tumors have an 
active IGF-1R11. IGF-1R is structurally similar to IR, sharing 84% homology across 
tyrosine kinase domains16. High levels of IGF-1 activity have been shown in TNBC cell 
lines and these findings have increased efforts to target IGF-1R activity for TNBC 
therapy17.  
Early clinical trials focused on IGF-1R/IR inhibition proved ineffective as 
monotherapy. A phase II clinical trial investigating the use of AXL1717, a small-
molecule modulator of IGF-1R signaling, on non-small cell lung cancer found AXL1717 
did not demonstrate significant benefit on progression-free or overall survival when used 
as a monotherapy18. Similarly, another study investigating the use of linsitinib, another 
IGF-1R inhibitor, on patients with relapsed small-cell lung cancer, found that although its 






 In response to nutrients and growth factors, the mammalian target of rapamycin 
(mTOR) functions to regulate cell growth and metabolism20. The mTOR complexes are 
downstream components of the PI3K/AKT pathway which forms two functionally distinct 
complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) that both 
play an important role in tumorigenesis21.  
mTORC1 is composed of several distinct components including mTOR, 
regulatory associated protein with mTOR (RAPTOR), and mammalian lethal with Sec13 
protein 8 (mLST8), DEP domain containing mTOR interacting protein (DEPTOR), 
proline-rich AKT substrate of 40 kDa (PRAS40)20. mTORC1 is responsive to several 
factors including energy and oxygen levels, amino acids, and growth factors. When 
glucose and intracellular ATP levels are high, mTORC1 is active; conversely, low 
energy and ATP levels act as an mTORC1 inhibitor22. Through phosphorylation of its 
downstream targets, ribosomal protein S6 kinase 1 (S6K1) and Lipin1, mTORC1 
activates sterol regulatory element binding factor 1 (SREBP1), a transcription factor 
involved in lipid synthesis22. A study conducted by Ricoult et al. in 2016 demonstrated 
that inhibition of mTORC1-mediated activation of SREBP1 led to stunted lipogenesis in 
BC cells, thus reducing cellular proliferation and tumor growth23. Additionally, mTORC1 
is responsible for regulating protein synthesis and plays an overall important role in cell 
growth/metabolism6,21.  
Similar to mTORC1, mTORC2 contains mTOR, mLST8, and Deptor but is also 
comprised of rapamycin insensitive companion of mTOR (Rictor), mSIN1, and Protor-
1/220,24. Following treatment with neoadjuvant chemotherapy, TNBCs have displayed 
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amplification of Rictor in residual disease22.Through phosphorylation of protein kinases 
belonging to the PKA/PKG/PKC (AGC) family, mTORC2 is involved in controlling cell 
proliferation/survival20. mTORC2 also plays a critical role in AKT activation which 
promotes cell survival and proliferation20. mTORC2 exists in a positive feedback loop 
with PI3K and AKT whereby the partial activation of PI3K and AKT promotes mTORC2 
activation and subsequently fully activates AKT25. Furthermore, mTORC2 increases 
IGF-1R/IR phosphorylation26.  
Given mTOR’s important role in cell growth and tumor progression, mTOR 
inhibitors have emerged as promising potential treatments in cancer therapy. These 
include rapamycin and everolimus, which allosterically inhibit mTORC127. Everolimus 
has been approved for use in several cancers including BC27. However, because 
everolimus specifically targets mTORC1, its use as a monotherapy has been associated 














Figure 1. Activation of the PI3K/AKT/mTOR pathway is critical in TNBC. 
Binding of IGF-1/IR to receptors, IGF-1R and IR, triggers the MAPK and PI3K/AKT 
pathway, which then activates the downstream targets, mTORC1 and S6, ultimately 
leading to cell growth and proliferation and protein synthesis/regulation.  
 
Obesity Increases Risk of Breast Cancer Development and Progression 
 
Obesity is a major public health concern in the United States as it is projected 
that by 2030, half of the US population will be obese and nearly 25% of all adults will be 
severely obese29. Importantly, nearly 20% of U.S. cancer diagnoses are related to 
excess body weight30. Obese women represent a unique and expanding patient 
population as obesity is associated with worse outcomes in patients bearing BC, and 
obese patients are at greater risk of developing TNBC than non-obese women31,32. The 
negative outcomes associated with obesity and BC include not only increased mortality 
but also a shorter time to disease recurrence33. A 2015 study conducted by Copson et 
al. found that obese patients with BC, defined as having a BMI>30kg/m2 had 
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significantly larger median tumor size compared to healthy weight individuals, defined 
as having a BMI<25kg/m234. Furthermore, the incidence of ER/PR/HER-2 negative 
tumors matching the TNBC subtype was 25.0% compared to 18.3% in healthy weight 
individuals34.  
There are several mechanisms by which obesity impacts BC initiation, 
progression, and metastasis including increased bioavailability of IGF-1 and increased 
stimulation of the PI3K/Akt/mTOR signaling pathway35,36. Obese patients often have 
some degree of insulin resistance and increased levels of circulating insulin as well as 
IGF-1 which contribute to a greater risk of developing BC36. Increased insulin levels can 
not only directly activate pro-growth signaling pathways but also reduce IGF binding 
protein (IGFBP), which binds to and inhibits IGF-1 under normal conditions. Thus, IGF-1 
levels increase and as previously mentioned, bioavailable IGF-1 can bind to IGF-1R to 
trigger downstream signaling cascades such as the PI3K/AKT/mTOR pathway which 
promotes tumor growth and progression37. A study conducted by Chen et al. found that 
genetically obese or diet-induced obese mice injected with E0771 (basal-like) BC cells 
showed upregulated expression of mTOR in mammary tumors compared to mice fed a 
normal chow diet38. 
In addition to increasing insulin/IGF-1 levels, the obese state is also associated 
with increased preadipocyte formation which leads to higher leptin production that 
favors pro-tumorigenic angiogenesis and mitogenesis33. Increased adipokines in the 
obese state also promote inflammation primarily through the nuclear factor kappa B 
(NF-κB) pathway which activates gene expression encoding the pro-inflammatory 
cytokines: interleukin 6 (IL-6), interleukin 8 (IL-8) and tumor necrosis factor alpha (TNF-
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α)33,39. These pro-inflammatory cytokines promote invasion and metastasis that 
contributes to poor patient outcomes in those with TNBC39. A study conducted by 
Hartman et al. in 2013 found that inhibition of IL-6 and IL-8 in MDA-MB-231 cells, a 
model of TNBC, resulted in significantly decreased anchorage-independent colony 
formation40. 
Thus, obesity promotes TNBC progression via numerous tumor cell intrinsic and 
extrinsic mechanisms. As obesity incidence in the U.S. continues to rapidly increase, 
these factors emphasize a need for treatments to specifically target obesity related 
TNBC progression. 
Nutrient Restrictive Interventions and Metabolic Reprogramming in Breast Cancer 
 
A growing area of nutrition and cancer research, with the potential to improve 
cancer outcomes is dietary modification such as calorie restriction (CR) and intermittent 
fasting (IF). Though these two dietary modifications both provide several beneficial 
effects resulting in extended lifespan and delayed onset of age-related disorders, they 
elicit distinct effects on normal and tumor cells41. CR is commonly defined in mouse 
models as a reduction (~30%) in total caloric intake without risk of developing 
malnutrition whereas IF is defined as the total avoidance of calories for a defined period 
of time41,42.  
The use of CR has extensively been shown to induce antitumorigenic effects in 
rodent models of BC41. Moreover, parallel studies investigating the use of CR diet in 
rhesus monkeys showed a significant reduction cancer incidence in monkeys fed a CR 
diet compared to control diet thus providing promising evidence that the benefits 
associated with CR are translatable to humans43. There are several mechanisms by 
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which CR mediates its beneficial effects including decreased growth factor and anabolic 
hormone production, especially IGF-1, as well as a reduction in pro-inflammatory 
cytokines and leptin production41,44. The Hursting lab has previously investigated the 
effects of CR on IGF-1 response in a murine model of colon cancer44. Female C57BL/6 
mice randomized to receive a 30% CR or control diet were injected with MC38 colon 
tumor cells. Mice fed the CR diet not only showed decreased body fat/weight and tumor 
incidence but also showed lower levels of serum IGF-1 and insulin. Further analysis of 
tumors from CR mice revealed decreased expression of the pro-inflammatory cytokines 
IL-6 and TNF-α44.  
In contrast to CR, in which there is a chronic calorie deficit, IF results in the 
depletion of glycogen stores from the liver to provide energy. When glycogen stores are 
emptied, the body relies on the catabolism of amino acids and fatty acids to provide 
energy in the form of glucose and ketone bodies45. Like CR, IF also results in reduced 
IGF-1 levels, mediated by increased circulating IGFBP-1, which binds to IGF-1 
preventing its interaction with IGF-1R46. Data suggests that IF results in greater 
reduction of glucose levels compared to those associated with CR47. IF also results in 
decreased circulating leptin, which is a hormone that inhibits hunger but causes an 
increase in adiponectin, which results in increased breakdown of fatty acids46. The 
beneficial effects of IR have also been shown to increase sensitization to some 
chemotherapeutic agents in preclinical TNBC murine models. A study conducted by de 
Groot et al. in 2015 investigated the effects of short-term fasting (24 hours) before and 
after receiving (neo)-adjuvant TAC (docetaxel/doxorubicin/cyclophosphamide) on 
patients with early-stage BC. They concluded that short-term fasting during 
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chemotherapy was well tolerated and reduced the hematological toxicity of TAC in 
HER2-negative BC patients48. 
While dietary interventions in the form of CR and IF have shown beneficial 
effects in preclinical murine models, there remain challenges in translating to cancer 
patients45. It is difficult to translate CR interventions from mice to humans, and there are 
concerns about the feasibility of implementing such extreme diets in patients due to the 
potential weight loss and discomfort that may result45,49. Because of these concerns, 
there is interest in identifying pharmacologic approaches, or metabolic reprogramming 
interventions (MRIs), which can be combined in innovative ways to recapitulate some or 
most of the beneficial effects of CR but with fewer challenges impacting adherence. 
Targets of the IGF-1 and AKT/mTOR pathways are of particular interest due to the role 
of these pathways in mediating CR and IF’s anticancer effects50.  
The FDA-approved everolimus (formerly called RAD001), an analog of 
rapamycin, is a pharmacological agent that works as an mTORC1 inhibitor (Fig. 2). 
Everolimus is currently being tested in several clinical trials and has been approved for 
use in the treatment of refractory renal cell carcinoma and pancreatic neuroendocrine 
tumors as well as some BCs51–53. The use of everolimus in TNBC therapy is limited but 
a study conducted by Yunokawa et al. in 2012 investigated the effect of everolimus in a 
nine TNBC cell lines. The results showed that everolimus inhibited cell growth in vitro in 
five of the nine TNBC cell lines54. Furthermore, this study investigated the effects of 
everolimus in vivo in a mouse xenograft model of TNBC using MDA-MB-231 and MDA-
MB-468 cells. Mice were treated with everolimus three times per week for three weeks, 
and the results showed that everolimus significantly reduced tumor volume of the MDA-
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MB-468 but not the MDA-MB-231 xenografts54. Although everolimus has demonstrated 
growth inhibitory effects, it is generally ineffective when used alone in treatment of 
TNBC (need ref), and further experimentation is needed to fully understand ways to 
enhance its beneficial effects. 
In addition to everolimus, BMS-754807 which works as a reversible dual small-
molecule inhibitor of both IGF-1R and IR, provides another promising option as a 
mimetic of the beneficial antitumor effects of CR (Fig. 2). In preclinical trials, BMS-
754807 has demonstrated efficacy in vitro for the treatment of a variety of human 
cancers including BC, pancreatic, colon, and lung cancer55. A 2012 study conducted by 
Awasthi et al. studied the combination of gemcitabine, a DNA synthesis inhibitor and 
BMS-754807 in mice injected with human pancreatic ductal adenocarcinoma (PDAC) 
xenografts. The results showed that while gemcitabine treatment alone inhibited the 
growth of PDAC xenografts, BMS-754807 enhanced the gemcitabine inhibitory 
response56. Although numerous clinical trials have made use of IGF-1/IGF-1R inhibitors, 
they have not demonstrated much benefit when used as single agents (ref). Thus, the 
ability of pharmacological agents to target IGF-1 and mTORC1 provides a promising 





Figure 2. PI3K/AKT/mTOR signaling can be inhibited by everolimus or BMS-
754807. 
BMS-754807 works as a dual small-molecule inhibitor of both IGF-1R and IR while 
everolimus works as an mTORC1 inhibitor.  
 
Autophagy’s Role in Cancer 
 
Autophagy is a highly conserved cellular process involved in the degradation of 
cellular material that can subsequently be recycled to provide energy for the cell57. This 
thesis will focus on the most well-studied form of autophagy, macroautophagy (hereafter 
referred to as autophagy), in which cellular contents are first sequestered in double-
membrane-bound vesicles known as autophagosomes, a process regulated by 
autophagy-related genes (Atg)58,59. The autophagosomes fuse with lysosomes forming 
autolysosomes whose contents are degraded and recycled58. Autophagy is 
predominantly regulated by AMP-activated protein kinase (AMPK) and mTOR, 
downstream of the PI3K/AKT signaling cascade, which plays a major role in cellular 
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energy balance60,61. When nutrients are plentiful and energy stores are high, mTOR 
works to inhibit autophagy57. Conversely, during times of nutrient depletion or starvation, 
AMPK is activated while mTOR is inhibited due to less glucose transport and amino 
acid availability resulting in induction of autophagy41,57. Thus, under CR conditions, 
autophagy is a key homeostatic process necessary for removing damaged or redundant 
organelles, which in turn generates metabolites for energy or macromolecule 
production41. A 2016 study conducted by Pietrocola et al. investigated the effects of 
caloric restriction mimetics defined as pharmacological agents that reduce protein 
acetylation to increase autophagic activity on autophagy induction. They found that 
hydroxycitrate, an over-the-counter weight loss agent mimicking CR, induced autophagy 
in vivo in mice when injected62. 
In cancer, autophagy’s role is complex, and its effects vary depending on the 
stage of cancer progression59. In the early stages of tumorigenesis, deletion of beclin 1 
(BECN1), a protein necessary for autophagy induction, tumor induction/progression has 
been shown to be enhanced58,59. However, in established tumors, autophagy can be 
upregulated to protect against and overcome various cellular stressors and promote 
tumor progression63,64. As tumors continue to grow, cells located centrally within the 
tumor often experience dysfunctional vascularization; thus, autophagy acts as a 
compensatory mechanism allowing cancer cells to generate metabolic fuels to survive 
in hypoxic or low-nutrient environments58. 
Autophagy’s ability to promote growth in established tumors provides a 
compelling argument for investigating the use of autophagy inhibition in cancer therapy, 
especially when considering that many current cancer treatments induce metabolic 
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stress that upregulates autophagy. Furthermore, as previously mentioned, CR results in 
an increased dependence on autophagy that, when combined with autophagy inhibition, 
may result in reduced tumor burden. The Hursting lab has previously investigated the 
use of autophagy inhibition alone and in combination with CR on Ras-driven tumors and 
found that combining a CR diet with autophagy inhibition resulted in greater tumor 
suppression than either CR or autophagy inhibition alone65. Many preclinical studies 
have also investigated the potential for exploiting increased autophagic activity under 
conditions of metabolic stress to improve the efficacy of autophagy inhibitors and 
existing chemotherapies. These studies commonly utilize the FDA-approved 
chloroquine (CQ) or hydroxychloroquine (HCQ), which work as autophagy inhibitors 
through deacidification of the lysosome to block autophagosome-lysosome fusion57. 
One of the first studies to demonstrate the ability of autophagy inhibition to enhance the 
anticancer effects of other therapies was a 2007 study conducted by Amaravadi et al. 
that utilized a Myc-induced model of lymphoma whose p53 mutant tumor cells were  
resistant to apoptosis. Treatment with tamoxifen resulted in p53 reactivation with 
increased apoptosis as well as the induction of autophagy. Subsequent inhibition of 
autophagy via CQ treatment or ATG5 shRNAs in combination with alkylating agents 
resulted in increased cell death66.  
The potential for autophagy inhibitors such as CQ to further enhance anticancer 
therapies provides a rationale for further investigating the use of CQ in combination with 
chemotherapy or pharmacological agents associated with growth factor signaling 
(mTOR) inhibition. Although chemotherapy is the standard-of-care treatment for patients 
with TNBC, many patients will develop resistance to treatment and CQ has shown 
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promise in overcoming chemotherapeutic resistance67. A 2014 study conducted by 
Chittaranjan et al. investigated the effects of combining the anthracycline, epirubicin, 
with HCQ treatment in both epirubicin-resistant and sensitive TNBC cells. The 
combination of epirubicin with HCQ increased therapeutic efficacy and also resulted in 
significantly reduced tumor growth compared to either epirubicin or HCQ treatment 
alone68. 
Given the importance of nutrient-sensing pathways including IGF-1 and mTOR 
on the tumor environment and its metabolic responses, this thesis proposes the use of 
pharmacological compounds to treat TNBC, termed metabolic reprogramming 
interventions, in combination with traditional cytotoxic platinum chemotherapy. 
Identification of pharmacological approaches that recapitulate the beneficial biochemical 
effects of dietary energy restriction has the potential to improve current TNBC treatment 
by increasing the efficacy of existing chemotherapy treatments. We will also investigate 
the effects of combining CQ with the aforementioned pharmacological agents, BMS-
754807 and everolimus. We hypothesized that inhibition of the IGF-1R/IR and mTORC1 
pathways by BMS-754807 and everolimus, respectively, stimulates autophagy and thus, 
combining these agents with CQ or carboplatin could potentially block the survival 
mechanism of TNBC cells. 
Project Goals 
 
 The goals of the project are as follows: 1) Determine whether metabolic 
reprogramming via IGF-1R/IR or mTORC1 inhibition enhances TNBC response to 
platinum chemotherapy. 2) Determine whether metabolic reprogramming interventions 
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CHAPTER 2: METABOLIC REPROGRAMMING INTERVENTIONS INHIBITING IGF-




Cell Lines Used 
 The human breast cancer cell line, MDA-MB-231 (ATCC HTB-26) derived from 
breast adenocarcinoma, was cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 4.5g/L glucose supplemented with 10% fetal bovine serum (FBS) and 2mM 
L-glutamine. Cells were maintained at 37ºC in a humidified 5% CO2 chamber. 
MTT Assay 
MDA-MB-231 cells were seeded (1x104 cells/well) in a 96-well plate overnight in 
glucose-restricted (1g/L) media for 24 hours, then treated with either everolimus or 
BMS-754807 across a range of doses for 24 hours, and finally treated with carboplatin 
for an additional 48 hours resulting in a 72-hour total treatment time. Media was 
aspirated and cells were incubated in a solution containing 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (0.5mg/mL) in PBS. After 1.5 hours. MTT 
reagent was removed and cells and precipitate solubilized with dimethyl sulfoxide 
(DMSO) and agitated on a plate shaker for 10 minutes. Absorbance was measured at 
570 and 690 nm via a Cytation 3 Cell Imaging Reader (BioTek).  
Western Blotting  
To confirm target inhibition following treatment with BMS-754807 or everolimus, 
MDA-MB-231 cells (2.1x106 cells/plate) were seeded into 10cm plates to achieve 70% 
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confluency after 24 hours. Cells were then treated with low-glucose (1g/L) DMEM 
containing either everolimus (15.63nM) or BMS-754807 (5µM). After treatment for 4 
hours, whole cell lysates were generated using radioimmunoprecipitation (RIPA) buffer 
supplemented with protease inhibitor cocktail (Sigma Aldrich) and phosphatase 
inhibitors (sodium orthovanadate, sodium pyrophosphate, β-Glycerophosphate). Cells 
were scraped from plates, incubated on ice for 20 minutes, and centrifuged at 24,000 rcf 
for 15 minutes at 4°C. The protein-containing supernatant was collected, and a Bradford 
assay (BioRad) was performed to determine protein concentration. Equal amounts of 
protein were added to solution containing 5X Loading Buffer (BioRad) and 5% 𝛽-
mercaptoethanol. Protein was then separated via SDS-PAGE and transferred to PVDF 
membrane (Bio-Rad). Membranes were blocked with 5% bovine serum albumin (BSA) 
in Tris Buffered Saline with 0.1% Tween (TBST) for 1 hour before being incubated 
overnight at 4°C with primary antibody. After washing with TBST, membranes were 
blocked in secondary IRDye 680 RD goat anti-mouse (LI-COR #926-68070, 1:10000) or 
IRDye 800CW goat anti-rabbit antibody (LI-COR #926-32211, 1:10000) for 1 hour at 
room temperature. Excess secondary antibody was removed by TBST washes. 
Antibody binding was detected with the Odyssey Imaging System (LI-COR). Images 
were analyzed via near-infrared fluorescence using Image J software according to NIH 
gel analysis procedures69. The following primary antibodies were used: p-AKT S473 
(CST #4060S, 1:1000), Akt (CST #9272S, 1:1000), pIGF-1R (CST #3918S, 1:1000), 
IGF-1R (CST #3027S, 1:1000), p-S6 Ser 235/236 (CST #2211S, 1:1000), S6 (CST 




MitoSOX Red mitochondrial superoxide indicator 
 MDA-MB-231 cells were seeded (4.25x105 cells/well) in a 6-well plate overnight 
in low-glucose (1g/L) media, then treated with BMS-754807 (2.5μM) or everolimus 
(15.63nM) for 4 hours. Cells were then trypsinized (Trypsin-EDTA, 0.25%, Gibco) and 
stained using MitoSOX red mitochondrial superoxide indicator (Invitrogen #M36008, 
1:500) diluted in FACS buffer + Menadione dye (Sigma Aldrich #M5625, 1:1000), + 
Zombie NIR Fixable Viability Kit (BioLegend #B331244, 1:600). Following 30 minutes of 
staining, data was acquired using a CytoFLEX flow cytometer (Beckman Coulter). Laser 
excitation at 488 nm was used to capture 10,000 single cell live events for each sample.  
MitoTracker Green FM indicator 
MDA-MB-231 cells were seeded (3.9x105 cells/well) in a 6-well plate overnight in 
low-glucose (1g/L) media, then treated with BMS-754807 (2.5μM) or everolimus 
(15.63nM) for 24 hours. Cells were then trypsinized (Trypsin-EDTA, 0.25%, Gibco) and 
stained using MitoTracker Green FM indicator (Invitrogen #M36008, 1:2000) diluted in 
FACS buffer + Zombie NIR Fixable Viability Kit (BioLegend #B331244, 1:600). 
Following 30 minutes of staining, data was acquired using a CytoFLEX flow cytometer 
(Beckman Coulter). Laser excitation at 488 nm was used to capture 10,000 single cell 
live events for each sample. 
TMRM indicator 
MDA-MB-231 cells were seeded (4.25x105 cells/well) in a 6-well plate overnight 
in low-glucose (1g/L) media, then treated with BMS-754807 (2.5μM) or everolimus 
(15.63nM) for 4 hours. Cells were then trypsinized (Trypsin-EDTA, 0.25%, Gibco) and 
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stained using TMRM reagent (Sigma Aldrich #T5428, 1:5000) diluted in FACS buffer + 
FCCP reagent (Sigma, 10nM), + Zombie NIR Fixable Viability Kit (BioLegend 
#B331244, 1:600). Following 30 minutes of staining, data was acquired using a 
CytoFLEX flow cytometer (Beckman Coulter). Laser excitation at 488 nm was used to 
capture 10,000 single cell live events for each sample. 
Statistical Analysis 
 Data were analyzed using GraphPad Prism 8 software (GraphPad Software, 
Inc.). Additionally, SynergyFinder software was utilized to determine synergy via the 
Bliss independence model. Differences between means were assessed via one-way 
analysis of variance (ANOVA) with Tukey’s multiple comparisons for statistical 
differences. Differences were considered significant at p<0.05.  Data graphically 
presented as mean ± standard error of mean (SEM) unless otherwise noted. 
Results 
 
Metabolic reprogramming via BMS-754807 or everolimus reduced cellular viability 
of human-derived triple-negative breast cancer cells 
 
To determine whether metabolic reprogramming interventions inhibited triple-
negative BC cell growth, we tested the effects of the dual IGF-1R/IR inhibitor, BMS-
754807, and the mTORC1 inhibitor, everolimus, on the viability of MDA-MB-231 TNBC 
cells cultured under low-glucose (1g/L) conditions, for 24 hours. Low-glucose media 
was used for experimental analyses to model and investigate response to therapies 
under conditions consistent with homeostatic glucose levels in a normoglycemic 
individual. Cellular viability was assessed via MTT viability assay which measures the 
reduction of a yellow tetrazolium salt to purple formazan crystals to quantify the amount 
of metabolically active cells70. Following 24 hours of treatment with BMS-754807, MDA-
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MB-231 cells cultured in low-glucose media showed significant growth inhibition at 
doses >2.5 μM (p<0.01 at 2.5μM, p<0.001 at 5μM) compared to control levels (Fig. 3A). 
Treatment with everolimus induced significant growth inhibition at doses >15.63nM 
(p<0.001 at 15.63nM, p<0.01 at 31.25nM, 62.5nM, and 125nM, p<0.05 at 250nM) 
compared to control levels (Fig. 3B). These results may be due to the overall limited 
growth inhibition of everolimus in the MDA-MB-231 cells. However, these results 
indicate that both BMS-754807 and everolimus have significant cytotoxic effects in 









Figure 3. MRIs alone are cytotoxic in MDA-MB-231 cells. 
Following 24 hours of culture in low-glucose (1g/L) media, MDA-MB-231 cells were 
treated with BMS-754807 at increasing doses of 0.625, 1.25, 2.5, 5 (p<0.01), and 10μM 
(p<0.001) (A) or everolimus at increasing doses of 15.63 (p<0.001), 31.25, 62.5, 125 
(p<0.01), and 250nM (p<0.05) (B) for 24 hours. An MTT assay was conducted to 
measure % growth inhibition/cytotoxicity. Data presented as mean ± SEM for n=3 
experiments.  
 
Metabolic reprogramming interventions inhibited anticipated metabolic targets 
 
 To confirm that everolimus and BMS-754807 treatment inhibited the metabolic 
signaling pathways they target, western blotting was performed to examine the amount 




















































of downstream protein targets following 4-hour incubation with each compound. 
Stimulation of IGF-1R activates the PI3K/AKT pathway11. Treatment with the dual IGF-
1R/IR inhibitor BMS-754807 (5μM) resulted in decreased phosphorylation of AKT in 
MDA-MB-231 cells (p<0.01) (Fig. 4A), indicating that the selected dose of BMS-754807 
is effective in impairing the IGF-1R/IR pathway. Furthermore, treatment with the 
mTORC1 inhibitor, everolimus (15.63nM) resulted in significantly decreased 
phosphorylation of ribosomal protein S6 (pS6) (p<0.0001) (Fig. 4B). Treatment with 
BMS-754807 also reduced pS6 levels (p<0.05) (Fig. 4B). Activated mTOR leads to the 
phosphorylation of S6; thus, these results indicate that the selected dose of everolimus 



















































Figure 4. MRIs inhibited anticipated metabolic targets. 
Confirmation of target inhibition in MDA-MB-231 cells treated with BMS-754807 and 
everolimus for 4 hours. Vector treatment with dimethyl sulfoxide (DMSO) serves as 
control for all experiments. Protein abundance was normalized to b-Actin loading 
control. Expression of pAKT (A), pS6 (B) analyzed. Representative western blots from 
n=3 experimental replicates for pAKT/AKT (C) and pS6/S6 (D). Data presented as 
mean + SEM. 
Mitochondria and reactive oxygen species analysis 
 
To analyze mitochondrial mass following treatment of MDA-MB-231 TNBC cells 
with BMS-754807 or everolimus, cells were stained with MitoTracker Green FM which is 
a probe that fluoresces more brightly in active mitochondria compared to apoptotic 
mitochondria, thus measuring mitochondrial mass71. Staining with MitoTracker Green 




























































treated with BMS-754807 compared to control and observed no difference in cells 






Figure 5. BMS-754807 treatment increased mitochondrial mass. 
Following 24 hours of culture in low-glucose (1g/L) media, MDA-MB-231 cells were 
treated with BMS-754807 (2.5μM) or everolimus (15.63nM) for 24 hours before being 
stained with MitoTracker Green FM. Median fluorescence intensity (A) with 
representative frequency histogram of cellular fluorescence; lower fluorescence 
indicates smaller mitochondrial mass (B). Data presented as mean ± SEM for n=3 
experiments.  
Next, to analyze mitochondrial superoxide production following treatment of 
MDA-MB-231 cells with BMS-754807 or everolimus, cells were stained with MitoSOX 
Red Reagent, a probe whose fluorescence increases as the concentration of 
superoxide increases72. There was no significant increase in mitochondrial superoxide 
production following treatment with either BMS-754807 or everolimus (Fig. 6A-B). We 
confirmed the functioning of the assay by treating cells with 50µM menadione for 30 min 











































Figure 6. MRIs did not affect mitochondrial superoxide production. 
Following 24 hours of culture in low-glucose (1g/L) media, MDA-MB-231 cells were 
treated with BMS-754807 (2.5μM) or everolimus (15.63nM) for 4 hours before being 
stained with MitoSOX Red Reagent. Median fluorescence intensity (A) with 
representative frequency histogram of cellular fluorescence; increased fluorescence 
indicates increased concentration of superoxide (B). Mitochondrial superoxide positive 
control achieved via menadione (MEN) treatment combined with MitoSOX Red Reagent 
(C) with representative frequency histogram of cellular fluorescence (D). Data presented 
as mean ± SEM for n=3 experiments.  
Finally, to analyze mitochondrial membrane potential following treatment of MDA-
MB-231 cells with BMS-754807 or everolimus, cells were stained with 
tetramethylrhodamine methyl ester (TMRM), a dye which fluoresces brightly and 
accumulates in healthy functioning mitochondria proportional to polarization, thus signal 



























































significant difference in mitochondrial membrane potential following treatment with 
either BMS-754807 or everolimus (Fig. 7A-B). We confirmed the functioning of the  
















Figure 7. MRIs did not affect mitochondrial membrane potential. 
Following 24 hours of culture in low-glucose (1g/L) media, MDA-MB-231 cells were 
treated with BMS-754807 (2.5μM) or everolimus (15.63nM) for 4 hours before being 
stained with tetramethylrhodamine (TMRM). Median fluorescence intensity (A) with 
representative frequency histogram of cellular fluorescence; decreased fluorescence 
indicates loss of mitochondrial membrane potential (B). Mitochondrial membrane 
negative control achieved via p-trifluoromethoxy carbonyl cyanide phenyl hydrazone 
(FCCP) treatment combined with TMRM (C) with representative frequency histogram of 



























































Metabolic reprogramming interventions enhance response to carboplatin 
Having confirmed reprogramming of metabolic signaling, and limited alterations 
to mitochondrial function we next combined metabolic reprogramming agents were with 
carboplatin in MDA-MB-231 cells to examine if enhanced growth inhibition occurs when 
combining metabolic reprogramming agents with platinum chemotherapy, using 
carboplatin as the model for platinum chemotherapy. MDA-MB-231 cells were treated 
for 24 hours with BMS-754807 or everolimus before the addition of carboplatin for 
another 48 hours leading to 72 hours total of treatment time. MDA-MB-231 cells showed 
enhanced growth inhibition at increasing doses of carboplatin compared to control 
















Figure 8. MRIs enhanced response to carboplatin. 
Following 24 hours of nutrient restriction in low-glucose (1g/L) media, MDA-MB-231 
cells were treated with BMS-754807 at increasing doses of 0.625, 1.25, 2.5, 5, and 
10μM (A) or everolimus at increasing doses of 15.63, 31.25, 62.5, 125, and 250nM (B). 
Following 24 hours of treatment, cells were also treated with 100, 200, or 400μg/mL 
carboplatin for an additional 48 hours. Vector controls for each group were treated with 
DMSO. An MTT assay was conducted to measure % growth inhibition/cytotoxicity. Data 
presented as mean ± SEM n=3 experiments. 
To investigate whether the combination of everolimus or BMS-754807 with 
carboplatin was synergistic, we assayed our data for synergistic interaction74. A 
synergistic effect occurs where the response from two drugs together is greater than the 
predicted response from the two drugs individually. It can be determined as the excess 
of observed effect over expected effect as calculated by several synergy scoring 
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models. The Bliss independence model was used for analysis which assumes that the 
fractional response of two drugs in combination equals the sum of the two fractional 
responses of each drug minus their product. We used SynergyFinder to calculate Bliss 
independence for each concentration, and thus a synergy score for the combination of 
two drugs over an average of all dose combination cells. For example, a synergy score 
of 15 corresponds to 15% of response beyond expectation. There is no particular 
threshold to define synergy but SynergyFinder defines that a score less than -10 likely 
indicates an antagonistic interaction between two drugs, a score from -10 to 10 likely 
indicates an additive interaction between two drugs, and a score greater than 10 likely 
indicates a synergistic interaction between two drugs75. 
The combination of BMS-754807 and carboplatin produced a synergy score of 
9.872 (Fig. 9A) while the combination of everolimus and carboplatin produced a 
synergy score of 9.354 (Fig. 9B). The highlighted boxes indicate the area where the 
most synergistic interaction is; for the combination of BMS-754807 with carboplatin, this 
occurs at a dose of 5μM BMS-754807 and 200μg/mL carboplatin. For the combination 
of everolimus with carboplatin, this occurs at a dose of 125nM everolimus and 
200μg/mL carboplatin. These scores indicate an additive interaction between BMS-
754807 or everolimus and carboplatin; however, they are close to the score of 10 
threshold needed to define a synergistic interaction. Since SynergyFinder calculates its 
scores over the entire concentration range, this average may be a conservative 
estimate of the synergistic potential between the reagents. Thus, there is likely potential 
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that BMS-754807 or everolimus work synergistically with carboplatin at concentrations 
focused on the identified areas of optimal interaction. 
Figure 9. Analysis of synergistic potential of MRIs in combination with 
carboplatin. 
Combination dose data of BMS-754807 and carboplatin analyzed utilizing 
SynergyFinder software with Bliss independence model. BMS-754807 in combination 
with carboplatin produced a Bliss synergy score of 9.872 (A) while everolimus in 











CHAPTER 3: AUTOPHAGY UNDERPINS SURVIVAL OF TNBC CELLS FOLLOWING 






MDA-MB-231 cells were seeded (1x104 cells/well) in a 96-well plate overnight in 
glucose-restricted (1g/L) media for 24 hours, treated with either everolimus or BMS-
754807 for 24 hours, and then treated with chloroquine for an additional 48 hours 
resulting in a 72-hour total treatment time. Media was aspirated and cells were 
incubated in a solution containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) (0.5 mg/mL) in PBS. After 1.5 hours. MTT reagent was removed and 
cells and precipitate solubilized with dimethyl sulfoxide (DMSO) and agitated on a plate 
shaker for 10 minutes. Absorbance was measured at 570 and 690 nm via a Cytation 3 
Cell Imaging Reader (BioTek).  
Flow Cytometry 
MDA-MB-231 cells were seeded (4.25x105 cells/well) in a 6-well plate overnight 
in low-glucose (1g/L) media, then treated with BMS-754807 (2.5μM) or everolimus 
(15.63nM) for 4 hours. Cells were then trypsinized (Trypsin-EDTA, 0.25%, Gibco) and 
stained using CYTO-ID Autophagy Detection Kit (Enzo Life Sciences, #51031-0050) 
according to the manufacturer’s protocol. Following 30 minutes of staining, data was 
acquired using a CytoFLEX flow cytometer (Beckman Coulter). Laser excitation at 488 




Metabolic reprogramming interventions do not alter autophagic activity in MDA-
MB-231 cells 
 
To analyze whether MDA-MB-231 TNBC cells treated with BMS-754807 or 
everolimus promote autophagy, cells were stained with CYTO-ID Green detection 
reagent which is a probe that fluoresces more brightly in vesicles produced during 
autophagy76. Staining with CYTO-ID Green detection reagent revealed an increase, 
although nonsignificant, in autophagic activity, (p<0.01) in MDA-MB-231 cells treated 
with BMS-754807 or everolimus compared to control (Fig. 10A-B). We confirmed the 
functioning of the assay by comparing cells stained with CYTO-ID Green detection 



















































Figure 10. BMS-754807 and everolimus did not alter autophagic activity. 
Following 24 hours of culture in low-glucose (1g/L) media, MDA-MB-231 cells were 
treated with BMS-754807 (2.5μM) or everolimus (15.63nM) for 4 hours before being 
stained with CYTO-ID Green detection reagent. Median fluorescence intensity (A) with 
representative frequency histogram of cellular fluorescence; decreased fluorescence 
indicates loss of mitochondrial membrane potential (B). Control compared to unstained 
control (C) with representative frequency histogram of cellular fluorescence (D). Data 
presented as mean ± SEM for n=3 experiments.  
 
Metabolic reprogramming interventions used in combination with autophagy 
inhibition enhances cytotoxic effects of BMS-754707 or everolimus alone 
Next, we examined the effect of chloroquine alone on the viability of MDA-MB-
231 cells cultured under glucose-restricted (1g/L) conditions for 24 hours. Growth 
inhibition was assessed via MTT assay. Following 48 hours of treatment with 
chloroquine, MDA-MB-231 cells showed significant cytotoxicity at a 30μM dose (p<0.01) 































































Figure 11. Chloroquine is cytotoxic in MDA-MB-231 cells. 
Following 24 hours of nutrient restriction in low-glucose (1g/L) media, MDA-MB-231 
cells were treated with chloroquine at 20 and 30μM (p<0.01). Control was low-glucose 
(1g/L) DMEM media. An MTT assay was conducted to measure % growth 
inhibition/cytotoxicity. Data presented as mean ± SEM n=3 experiments. 
 Chloroquine was next combined with BMS-754807 or everolimus in MDA-MB-
231 cells to examine if enhanced growth inhibition occurs when combining metabolic 
reprogramming agents with autophagy inhibition. MDA-MB-231 cells were treated for 24 
hours with BMS-754807 or everolimus before the addition of chloroquine for another 48 
hours leading to 72 hours total of treatment time. Following treatment, MDA-MB-231 
cells cultured in low-glucose media showed enhanced growth inhibition at increasing 












































Figure 12. BMS-754807 enhanced response to chloroquine. 
Following 24 hours of nutrient restriction in low-glucose (1g/L) media, MDA-MB-231 
cells were treated with BMS-754807 at increasing doses of 0.625, 1.25, 2.5, 5, and 
10μM (A) or everolimus at increasing doses of 15.63, 31.25, 62.5, 125, and 250nM (B). 
Following 24 hours of treatment, cells were also treated with 0, 20, or 30μM chloroquine 
(CQ) for an additional 48 hours. Controls for each group were low-glucose (1g/L) DMEM 
media vector treated with DMSO. An MTT assay was conducted to measure % growth 
inhibition/cytotoxicity. Data presented as mean ± SEM for n=3 experiments. 
To determine whether the combination of everolimus or BMS-754807 with 
chloroquine had a synergistic relationship, we again utilized SynergyFinder software to 
analyze synergistic potential via Bliss independence. The combination of BMS-754807 
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and chloroquine produced a synergy score of 9.592 (Fig. 13A), a score indicating an 
additive interaction between BMS-754807 and chloroquine. Again, the highlighted 
boxes indicate the area where the most synergistic interaction is; for the combination of 
BMS-754807 with chloroquine, this occurs at a dose of 0.625μM BMS-754807 and 
15μM chloroquine. There is likely potential for greater synergy if examining only the 
effects closer to this optimal combination of BMS-754807 and chloroquine. For the 
combination of everolimus with chloroquine, this occurs at a dose of 125nM everolimus 
and 20μM chloroquine. Surprisingly, the combination of everolimus and chloroquine 
produced a synergy score of -7.122. (Fig. 13B), indicating that treatment of everolimus 
with chloroquine is less effective than predicted and that everolimus and chloroquine 
are inhibiting each other’s cytotoxic effects.
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Figure 13. Analysis of synergistic potential of MRIs in combination with 
chloroquine. 
Combination dose data of BMS-754807 or everolimus and carboplatin analyzed utilizing 
SynergyFinder software with Bliss independence model. BMS-754807 in combination 
with chloroquine produced a Bliss synergy score of 9.592 (A) while everolimus in 
























As TNBC is frequently associated with abnormalities in the PI3K/AKT/mTOR 
signaling cascade, the use of IGF-1/IGF-1R and mTORC1 inhibitors presents a 
promising avenue in TNBC therapy. Few clinical trials have investigated the use of the 
mTORC1 inhibitor, everolimus, in TNBC. A phase II neoadjuvant study conducted by 
Gonzalez et al. studied the use of paclitaxel treatment followed with fluorouracil, 
epirubicin, cyclophosphamide (FEC) regiment alone or in combination with everolimus 
treatment in 50 women with TNBC. They concluded that there was a higher clinical 
response in patients treated with everolimus, paclitaxel, and FEC compared to 
paclitaxel and FEC treatment only, though this response was nonsignificant77. Although 
everolimus has been used in treatment of other BC subtypes, there is very limited 
evidence of its use in combination with carboplatin or other platinum-based compounds. 
A clinical phase I/II trial recently conducted by Park et al. investigated the use 
gemcitabine and cisplatin (another platinum containing chemotherapy) in combination 
with everolimus compared to gemcitabine and cisplatin treatment alone in metastatic 
TNBC patients. Though they demonstrated that patients with TNBC had PIK3CA 
mutations in cell-free blood DNA samples, their findings showed that everolimus did not 
act synergistically with gemcitabine/cisplatin78.  
Early clinical trials proved ineffective when using IGF-1/IGF-1R inhibition as 
monotherapy against various cancer types. A phase II clinical trial investigating the use 
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of AXL1717, a small-molecule modulator of IGF-1R signaling, in non-small cell lung 
cancer found AXL1717 did not demonstrate significant benefit on progression-free or 
overall survival when used as a monotherapy18. Similarly, another study investigating 
the use of linsitinib, another IGF-1R inhibitor, on patients with relapsed small-cell lung 
cancer, found that although its use was safe, linsitinib did not demonstrate any useful 
clinical activity19.   
 In this study, MDA-MB-231 TNBC cells were treated with BMS-754807 or 
everolimus to inhibit IGF-1/IGF-1R or mTORC1 respectively. Cells were cultured under 
low-glucose (1g/L) conditions to model and investigate response to treatment under 
conditions consistent with homeostatic glucose levels in a normoglycemic individual. 
Treatment of MDA-MB-231 cells with BMS-754807 or everolimus resulted in significant 
growth inhibition. One limitation of this study was everolimus’s limited overall growth 
inhibition; however, similar results were observed in vitro by Ariaans et al. who found 
that everolimus lost its sensitivity in inhibiting MDA-MB-231 cell growth under low-
glucose conditions. Overall, as expected, both BMS-754807 and everolimus resulted in 
significant growth inhibition, inducing metabolic stress and remodeling metabolism in 
TNBC cells.  
Because treatment options for TNBC are limited, acquired chemoresistance 
presents an obstacle in TNBC therapy67. IGF-1R signaling has also been implicated in 
mediating resistance to chemotherapy in ovarian, breast, prostate, and bladder 
cancers79. Thus, IGF-1/IGF-1R and mTORC1 inhibition remains of particular interest in 
TNBC for its potential to restore chemosensitivity.  
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IGF-1R signaling has also been implicated in mediating resistance to platinum-
based compounds as increased IGF-1R signaling has been shown to induce cisplatin 
resistance in ovarian cancer80. Furthermore, the PI3K/AKT signaling cascade has been 
implicated in mediating resistance to platinum-based compounds in both breast and 
ovarian cancer81. This study tested the hypothesis that IGF-1R/IR or mTORC1 inhibition 
enhances the response to platinum chemotherapy. Targeting the IGF-1R and mTORC1 
pathways which are frequently dysregulated in TNBC, demonstrated effectiveness in 
combination with carboplatin. BMS-754807 and everolimus both worked additively with 
carboplatin to achieve growth-inhibitory effects. This is in agreement with a study 
conducted by Xu et al. in 2020 which investigated the effects of paclitaxel, a taxane 
which is commonly used as part of first-line therapy for BC, alone and in combination 
with everolimus on MDA-MB-231 TNBC cells82. Their work demonstrated that 
everolimus increases the antiproliferative effects of paclitaxel treatment alone through 
increased growth inhibition, the induction of apoptosis, and downregulated mTOR 
signaling82. One major limitation of this study is that the results achieved may have been 
a conservative estimate of the synergistic potential between BMS-754807 or everolimus 
with carboplatin. To fully investigate the potential of synergy between these drugs, 
further studies should utilize concentrations focused more narrowly on the identified 
areas of optimal interaction. 
To further determine if BMS-754807 and everolimus reprogrammed cell 
metabolism, we analyzed mitochondrial mass, mitochondrial superoxide production, and 
mitochondrial membrane potential following treatment of MDA-MB-231 cells with BMS-
754807 or everolimus. The results showed that treatment with BMS-754807, not 
 41 
everolimus, led to a significant increase in mitochondrial mass compared to untreated 
cells which is in agreement with previous work conducted in the Hursting lab showing 
that MCF-7 BC cells exposed to BMS-754807 leads to a significant reduction in 
mitochondrial mass83. Although the mTOR complex has been shown to play an 
important role in regulating mitochondrial function and a study conducted by Schieke et 
al. demonstrated that treatment with rapamycin resulted in significantly reduced 
mitochondrial membrane potential, our results found that there was no significant 
difference in mitochondrial superoxide production or mitochondrial membrane potential 
following treatment with either BMS-754807 or everolimus84,85. Though our study did not 
show that treatment with BMS-754807 or everolimus resulted in significant 
mitochondrial effects, mitochondrial metabolism remains a promising area for cancer 
therapy. Mitochondrial metabolism plays a crucial role in generating ATP and TCA cycle 
intermediates which serve as precursors for the synthesis of macromolecules that can 
fuel cell growth and tumor proliferation86. On the other hand, cancer cells have the 
ability to switch between mitochondrial metabolism and glycolysis depending on nutrient 
status87. This metabolic flexibility is important as it has been associated with 
chemoresistance in cancer cells88. 
As dose-limiting toxicities during cytotoxic chemotherapy pose an obstacle to 
treatment due to the potential for the development of side effects including nausea, 
vomiting, gastrointestinal inflammation, and central/peripheral nervous system 
neurotoxicity, there is growing interest in other methods of remodeling cancer 
metabolism including dietary energy restriction89. For instance, fasting, calorie 
restriction, and the use of the ketogenic diet have all demonstrated antitumorigenic 
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benefits in rodent models48,65,90. Dietary energy restriction such as CR achieves its 
beneficial anticancer effects through several mechanisms including 
reduction/inactivation of growth factor signaling pathways such as the IGF-1 signaling 
cascade as well as decreased chronic inflammation and systemic leptin levels50. 
Importantly, obesity also results in metabolic remodeling through a constant state of 
hyperinsulinemia whereby growth hormone receptor and its related signaling cascades 
are upregulated leading to tumor growth and proliferation50. Obese patients with BC can 
develop chemoresistance to pharmacological/chemotherapeutic agents due to several 
factors including adipose tissue expansion resulting in increased pro-tumorigenic 
adipokines in addition to several other pro-survival factors91.  
In addition to dietary energy restriction, other metabolically directed agents have 
been used in combination with chemotherapy or other therapies to target cancer growth 
and progression. For instance, the IGF-1R inhibitor, picropodophyllin (PPP), has been 
used in combination with the FDA approved type II diabetes agent, metformin, and 
resulted in greater growth inhibition of endometrial cancer cells compared to either 
agent alone92. Furthermore, combination treatment of pemetrexed disodium, an 
antifolate agent, with cisplatin has shown promising results and has been well-tolerated 
in patients with advanced non-small cell lung cancer93. Thus, the use of combination 
approaches using pharmacological/chemotherapeutic interventions which target 
multiple pathways that maximize efficacy while minimizing harsh adverse effects 
continues to show promise in the prevention and treatment of cancer. 
As tumors develop, cancer cells face increased proliferative demands even in a 
tumor microenvironment characterized by dysfunctional vascularization and hypoxia 
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while cells compete for a limited supply of nutrients. To cope with these stressful 
conditions, cancer cells often utilize autophagy to generate metabolic fuels presenting a 
potential target for improving response to cancer therapy57. Furthermore, increased 
autophagic activity following therapy has been implicated in chemoresistance across 
multiple breast cancer subtypes94,95. This leads to the potential for combination 
therapies using autophagy inhibitors with cytotoxic therapies to overcome 
chemotherapeutic resistance. 
This study examined the hypothesis that BMS-754807 and everolimus and BMS-
754807, as inhibitors of IGF-1R/IR and mTORC1 respectively, induce autophagy. Our 
results showed a nonsignificant increase in autophagic activity in MDA-MB-231 cells 
treated with BMS-754807 or everolimus compared to untreated cells. Our findings agree 
with the work of Dayyani et al. which demonstrated that treatment of prostate cancer 
cells with BMS-754807 did not result in significant amounts of the protein LC3-II, which 
allows for the quantification of autophagosomes, suggesting autophagy may play a 
limited role in survival of MDA-MB-231 cells following BMS-754807 treatment96. 
However, further experiments using higher concentrations of BMS-754807 and 
everolimus may be necessary in order to better visualize and measure autophagic flux 
within treated cells.  
Next, we tested the hypothesis that autophagy underpins survival of MDA-MB-
231 cells by targeting metabolic pathways known to be dysregulated in TNBC, 
specifically through inhibition of IGF-1R/IR and mTORC1, followed by treatment with the 
autophagy inhibitor, chloroquine. Our findings demonstrated that metabolic 
reprogramming interventions used in combination with autophagy inhibition enhances 
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the cytotoxic effects of MRIs alone. BMS-754807 and chloroquine worked additively to 
inhibit MDA-MB-231 cell growth; however, we found that chloroquine and everolimus 
inhibited each other’s growth-inhibitory effects. A study conducted by Grimaldi et al. 
found that the combination of everolimus and chloroquine synergistically inhibited 
growth of endothelial progenitor cells97. Our findings do not agree with Grimaldi et al. as 
we did not find that the addition of chloroquine increased the growth-inhibitory effect of 
everolimus. However, as mentioned previously, a limitation of this study is that the 
results achieved may have been a conservative estimate of the synergistic potential 
between BMS-754807 or everolimus with chloroquine. Further experimentation using 
concentrations of BMS-754807 and chloroquine focused more narrowly on the identified 
areas of optimal interaction may reveal a true synergistic relationship between the two. 
This project is effective in informing future experiments that can further explore whether 
the combination of everolimus or BMS-754807 with chloroquine will be effective in 
TNBC treatment. Together, these studies highlight the potential of combining MRIs with 
carboplatin or chloroquine in triple-negative BC cells to improve current TNBC 
therapies. 
One limitation of this study is that all experiments were conducted in a single cell 
line. Furthermore, all experiments were conducted in two-dimensional (2D) cell culture. 
While 2D cell culture where cancer cells are grown in a monolayer provides useful initial 
information about the effectiveness of pharmacological agents and chemotherapy 
treatment, three-dimensional (3D) cell culture more accurately mimic the in vivo tumor 
microenvironment. 2D cell culture leads to more flattened cell morphology and cell-cell 
and cell-extracellular environment interactions of cells grown in a monolayer do not 
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match those of cells in a 3D environment98. These changes can affect cellular function, 
intracellular cell structure, as well as cell signaling/secretion99. For these reasons, the 
development of 3D cell culture is useful as a more physiologically relevant model of the 
tumor microenvironment. Tumor spheroids have been shown to more faithfully 
recapitulate in vivo tumor cell metabolism and signaling within the PI3K/AKT/mTOR 
signaling cascade100. Thus, tumor spheroids can serve as a better predictor of drug 
response in solid tumors100.  
Lastly, these experiments were unable to assess toxicity in response to the 
pharmacological agents and chemotherapy used. Future experiments will explore the 
effects of MRIs and chemotherapy in a three-dimensional model of BC to confirm the 
efficacy of single agent and combination therapies and provide better prediction of in 
vivo response. MRIs that show efficacy in both two and three-dimensional analyses will 
then be tested in preclinical mouse models to confirm the effects of MRIs on factors 
such as metastasis and toxicity. 
Three-dimensional in vitro analyses 
 Our proposed 3D cell culture model includes tumor spheroids grown under non-
adherent conditions in a biologically relevant extracellular matrix to confirm the efficacy 
of single agent and combination therapies and provide better prediction of in vivo 
response. MDA-MB-231 cells will first be grown as a monolayer and then trysinized for 
seeding in ultra-low attachment plates in low-glucose DMEM. Tumor spheroids will be 
embedded in a Matrigel: type I collagen mixture (1:1). Following the treatment approach 
from the 2D cell culture model, spheroids will be treated with BMS-754807 or 
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everolimus for 24 hours followed by combination treatment with either carboplatin or 
chloroquine for 48 hours resulting in a 72-hour total treatment time.  
 Confirmation of target inhibition will be determined in un-embedded spheroids, 
which will undergo treatment for 4 hours with MRI alone or in combination with 
carboplatin or chloroquine. Spheroids will be collected using the Cultrex 3-D Culture 
Cell Harvesting Kit (Trevigen) for Western blotting. To analyze the extent of invasion of 
embedded spheroids into the surrounding extracellular environment, spheroids will be 
imaged using the ImageJ software. 
Animal Design Protocol 
 Eight-week-old wild-type female C57BL/6J mice (Jackson Laboratories) will be 
allowed to acclimate for one week before randomization to either a purified high fat diet 
(60% kcal from fat) or a low-fat control diet (10% kcal from fat). Body weight will be 
measured weekly from diet start to study endpoint. Body composition measurements 
will be taken at baseline and at tumor cell injection via Magnetic Resonance Imaging 
(MRI) conducted by the UNC Animal Metabolism Phenotyping Core. Following 15 
weeks on diet, E0771 cells (a C57BL/6 syngeneic line similar to MDA-MB-231) will be 
orthotopically injected into the 4th mammary fat pad of lean and obese mice. Tumor 
growth will be measured twice weekly with calipers with longitudinal and transverse 
diameters recorded. Once 50% of tumors within each diet group reach appropriate size 
(100mm3), mice will be randomized to the following treatment groups: 1) Vehicle-(saline) 
injected control, 2) Carboplatin only (20mg/kg twice weekly by intraperitoneal injection), 
3) MRI (BMS-754807 or everolimus) + carboplatin. Doses for in vivo MRI analyses will 
be chosen based on previous studies showing safety and efficacy in murine models. 
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Blood glucose will be monitored to ensure no excessive toxicity arising from BMS-
754807 treatment. Treatment will be given over a period of three weeks following a 
dosing schedule such as the one outlined below (Table 1): 
Table 1. Proposed treatment schedule for single-agent and combination therapies 
 
Day 1 2 3 4 5 6 7 
Group 1: 
Vehicle 
Vehicle Vehicle  Vehicle Vehicle   
Group 2: 
CP only 
Vehicle CP (20mg/kg)  Vehicle CP (20mg/kg)   
Group 3: 
BMS + CP 
BMS BMS + CP  BMS BMS + CP   
 
Planned Analysis 
 Upon completion of this study, animals will be sacrificed one week after the last 
treatment cycle or when any tumor reaches the IACAC defined maximum (> 2cm in any 
dimension). Primary tumor progression will be reported as change in volume during 
treatment period, with ex vivo tumor volume reported in mm3 and ex vivo tumor mass 
measured in mg. Tumors will be collected at sacrifice and a portion of each tumor 
frozen in liquid nitrogen for microarray analysis to identify differential expression of 
genes associated with metastasis and immune infiltration. Tumor histological sections 
will be examined via immunohistochemical (IHC) analysis. Lung and liver will be 
collected at sacrifice, and H&E-stained histological sections will be examined to assess 
metastatic burden. All histological outcomes will be conducted by the UNC Lineberger’s 





CHAPTER 5: CONCLUSIONS 
Project aims were designed to determine new approaches to treatment in triple-
negative breast cancer, which exhibits elevated recurrence and metastasis rates and 
poorer overall survival compared to other breast cancer subtypes. It was hypothesized 
that MRIs which recapitulate the beneficial effects conferred by calorie restriction 
through inhibition of IGF-1R/IR and mTORC1 signaling sensitize TNBC cells to 
chemotherapy or autophagy inhibition. We determined that IGF-1R/IR and mTORC1 
inhibition via BMS-754807 and everolimus respectively is potentially synergistic with 
carboplatin. Furthermore, we determined that BMS-754807 inhibits critical metabolism 
regulators in MDA-MB-231 TNBC cells and enhanced dependence on autophagy. 
However, further investigation is necessary to determine the optimal combinations of 
pharmacological agents with chemotherapy. Future experiments will explore the effects 
of MRIs and chemotherapy in a three-dimensional model of BC to confirm the efficacy 
of single agent and combination therapies and provide better prediction of in vivo 
response. MRIs that show efficacy in both two and three-dimensional analyses will be 
tested in preclinical mouse models to confirm the effects of MRIs on factors such as 
metastasis. Thus, this work will advance knowledge in bridging cellular and whole 






1.  Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J 
Clin. 2021;71(1):7-33. doi:10.3322/caac.21654 
 
 
2.  Bonotto M, Gerratana L, Poletto E, et al. Measures of Outcome in Metastatic 




3.  Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative 
breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin 
Invest. 2011;121(7):2750-2767. doi:10.1172/JCI45014 
 
 
4.  Yin L, Duan J-J, Bian X-W, Yu S. Triple-negative breast cancer molecular 




5.  Siddharth S, Sharma D. Racial Disparity and Triple-Negative Breast Cancer in 
African-American Women: A Multifaceted Affair between Obesity, Biology, and 




6.  Massihnia D, Galvano A, Fanale D, et al. Triple negative breast cancer: shedding 




7.  Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast 




8.  Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification 
of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug 




9.  Isakoff SJ. Triple-Negative Breast Cancer: Role of Specific Chemotherapy 
Agents. Cancer J. 2010;16(1):53-61. doi:10.1097/PPO.0b013e3181d24ff7 
 50 
10.  Jhan J-R, Andrechek ER. Triple-negative breast cancer and the potential for 




11.  Ekyalongo RC, Yee D. Revisiting the IGF-1R as a breast cancer target. NPJ 
Precis Oncol. 2017;1. doi:10.1038/s41698-017-0017-y 
 
 
12.  Yu H. Role of the Insulin-Like Growth Factor Family in Cancer Development and 
Progression. J Natl Cancer Inst. 2000;92(18):1472-1489. doi:10.1093/jnci/92.18.1472 
 
 




14.  Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J 
Cancer. 2003;107(6):873-877. doi:10.1002/ijc.11487 
 
 
15.  Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth 




16.  Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor 
signalling in cancer. Br J Cancer. 2005;92(12):2097-2101. doi:10.1038/sj.bjc.6602627 
 
 
17.  Litzenburger BC, Creighton CJ, Tsimelzon A, et al. High IGF-IR Activity in Triple-
Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–




18.  Bergqvist M, Holgersson G, Bondarenko I, et al. Phase II randomized study of 
the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with 
previously treated, locally advanced or metastatic non-small cell lung cancer. Acta 
Oncol. 2017;56(3):441-447. doi:10.1080/0284186X.2016.1253866 
 
 
19.  Chiappori AA, Otterson GA, Dowlati A, et al. A Randomized Phase II Study of 
Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung 
Cancer. The Oncologist. 2016;21(10):1163. doi:10.1634/theoncologist.2016-0220 
 51 
20.  Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. 
Cell. 2017;168(6):960-976. doi:10.1016/j.cell.2017.02.004 
 
 
21.  Jhanwar-Uniyal M, Wainwright JV, Mohan AL, et al. Diverse signaling 
mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable 
relationship. Adv Biol Regul. 2019;72:51-62. doi:10.1016/j.jbior.2019.03.003 
 
 
22.  Kim LC, Cook RS, Chen J. mTORC1 and mTORC2 in cancer and the tumor 
microenvironment. Oncogene. 2017;36(16):2191-2201. doi:10.1038/onc.2016.363 
 
 
23.  Ricoult SJH, Yecies JL, Ben-Sahra I, Manning BD. Oncogenic PI3K and K-Ras 




24.  Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr 
Opin Cell Biol. 2010;22(2):169-176. doi:10.1016/j.ceb.2009.10.007 
 
 
25.  Yang G, Murashige DS, Humphrey SJ, James DE. A Positive Feedback Loop 








27.  Lee JJ, Loh K, Yap Y-S. PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol 
Med. 2015;12(4):342-354. doi:10.7497/j.issn.2095-3941.2015.0089 
 
 
28.  O’Reilly KE, Rojo F, She Q-B, et al. mTOR Inhibition Induces Upstream Receptor 




29.  Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. State-Level Prevalence of 





30.  Rock CL, Thomson C, Gansler T, et al. American Cancer Society guideline for 




31.  Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast 




32.  Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk 
of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol 




33.  Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. 
Obesity and adverse breast cancer risk and outcome: Mechanistic insights and 




34.  Copson ER, Cutress RI, Maishman T, et al. Obesity and the outcome of young 




35.  Malley CO, Pidgeon GP. The mTOR pathway in obesity driven gastrointestinal 




36.  Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer 
development in obesity. Nat Rev Cancer. 2011;11(12):886-895. doi:10.1038/nrc3174 
 
 
37.  Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic 
insights from epidemiology. Nat Rev Cancer. 2015;15(8):484-498. doi:10.1038/nrc3967 
 
 
38.  Chen C-T, Du Y, Yamaguchi H, et al. Targeting the IKKβ/mTOR/VEGF Signaling 
Pathway as a Potential Therapeutic Strategy for Obesity-Related Breast Cancer. Mol 




39.  Dietze EC, Chavez TA, Seewaldt VL. Obesity and Triple-Negative Breast 




40.  Hartman ZC, Poage GM, den Hollander P, et al. Growth of triple-negative breast 
cancer cells relies upon coordinate autocrine expression of the proinflammatory 




41.  O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: 
calorie restriction and response to cancer therapy. BMC Med. 2017;15(1):106. 
doi:10.1186/s12916-017-0873-x 
 
42.  Longo VD, Fontana L. Calorie restriction and cancer prevention: metabolic and 




43.  Mattison JA, Colman RJ, Beasley TM, et al. Caloric restriction improves health 




44.  Harvey AE, Lashinger LM, Otto G, Nunez NP, Hursting SD. Decreased systemic 
IGF-1 in response to calorie restriction modulates murine tumor cell growth, nuclear 
factor-κB activation, and inflammation-related gene expression: CALORIE 




45.  Simone BA, Champ CE, Rosenberg AL, et al. Selectively starving cancer cells 




46.  Nencioni A, Caffa I, Cortellino S, Longo VD. Fasting and cancer: molecular 




47.  Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer 
treatment: from model organisms to patients. Oncogene. 2011;30(30):3305-3316. 
doi:10.1038/onc.2011.91 
 54 
48.  de Groot S, Vreeswijk MPG, Welters MJP, et al. The effects of short-term fasting 
on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: 
a randomized pilot study. BMC Cancer. 2015;15:652. doi:10.1186/s12885-015-1663-5 
 
 
49.  Ingram DK, de Cabo R. Calorie restriction in rodents: Caveats to consider. 
Ageing Res Rev. 2017;39:15-28. doi:10.1016/j.arr.2017.05.008 
 
 
50.  Hursting SD, Dunlap SM, Ford NA, Hursting MJ, Lashinger LM. Calorie 




51.  Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal 
cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. The 
Lancet. 2008;372(9637):449-456. doi:10.1016/S0140-6736(08)61039-9 
 
 
52.  Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting 
repeatable for the treatment of advanced neuroendocrine tumours associated with 
carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. 
The Lancet. 2011;378(9808):2005-2012. doi:10.1016/S0140-6736(11)61742-X 
 
 
53.  Royce M, Bachelot T, Villanueva C, et al. Everolimus Plus Endocrine Therapy for 
Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth 




54.  Yunokawa M, Koizumi F, Kitamura Y, et al. Efficacy of everolimus, a novel 




55.  Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of 




56.  Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE. BMS-754807, a Small-
Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances 
Gemcitabine Response in Pancreatic Cancer. Mol Cancer Ther. 2012;11(12):2644-
2653. doi:10.1158/1535-7163.MCT-12-0447 
 55 
57.  Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev 
Cancer. 2017;17(9):528-542. doi:10.1038/nrc.2017.53 
 
 
58.  Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer 








60.  Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat 
Rev Cancer. 2007;7(12):961-967. doi:10.1038/nrc2254 
 
 
61.  Rebecca VW, Amaravadi RK. Emerging strategies to effectively target autophagy 
in cancer. Oncogene. 2016;35(1):1-11. doi:10.1038/onc.2015.99 
 
 
62.  Pietrocola F, Pol J, Vacchelli E, et al. Caloric Restriction Mimetics Enhance 




63.  Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding 




64.  Xia H, Green DR, Zou W. Autophagy in tumour immunity and therapy. Nat Rev 
Cancer. Published online March 23, 2021. doi:10.1038/s41568-021-00344-2 
 
 
65.  Lashinger LM, O’Flanagan CH, Dunlap SM, et al. Starving cancer from the 
outside and inside: separate and combined effects of calorie restriction and autophagy 




66.  Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-
induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 
2007;117(2):326-336. doi:10.1172/JCI28833 
 56 
67.  Kim C, Gao R, Sei E, et al. Chemoresistance Evolution in Triple-Negative Breast 




68.  Chittaranjan S, Bortnik S, Dragowska WH, et al. Autophagy Inhibition Augments 
the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant 








70.  Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the MTT Assay. 
Cold Spring Harb Protoc. 2018;2018(6):pdb.prot095505. doi:10.1101/pdb.prot095505 
 
 
71.  Doherty E, Perl A. Measurement of Mitochondrial Mass by Flow Cytometry 




72.  Kauffman ME, Kauffman MK, Traore K, et al. MitoSOX-Based Flow Cytometry for 









74.  Roell KR, Reif DM, Motsinger-Reif AA. An Introduction to Terminology and 
Methodology of Chemical Synergy—Perspectives from Across Disciplines. Front 
Pharmacol. 2017;8:158. doi:10.3389/fphar.2017.00158 
 
 
75.  Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for 




76.  Guo S, Liang Y, Murphy SF, et al. A rapid and high content assay that measures 
cyto-ID-stained autophagic compartments and estimates autophagy flux with potential 
 57 




77.  Gonzalez-Angulo AM, Akcakanat A, Liu S, et al. Open-label randomized clinical 
trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the 
combination of paclitaxel and everolimus followed by FEC in women with triple receptor-




78.  Park IH, Kong S-Y, Kwon Y, et al. Phase I/II clinical trial of everolimus combined 




79.  Yuan J, Yin Z, Tao K, Wang G, Gao J. Function of insulin-like growth factor 1 




80.  Eckstein N, Servan K, Hildebrandt B, et al. Hyperactivation of the Insulin-like 
Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin 




81.  Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp 
Clin Cancer Res. 2011;30(1):91. doi:10.1186/1756-9966-30-91 
 
 
82.  Xu T, Liu P, Li Q, Shi C, Wang X. Inhibitory effects of everolimus in combination 
with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231. Taiwan J 
Obstet Gynecol. 2020;59(6):828-834. doi:10.1016/j.tjog.2020.09.008 
 
 
83.  Lyons A, Coleman M, Riis S, et al. Insulin-like growth factor 1 signaling is 




84.  Schieke SM, Phillips D, McCoy JP, et al. The Mammalian Target of Rapamycin 
(mTOR) Pathway Regulates Mitochondrial Oxygen Consumption and Oxidative 
Capacity. J Biol Chem. 2006;281(37):27643-27652. doi:10.1074/jbc.M603536200 
 58 
85.  Morita M, Gravel S-P, Hulea L, et al. mTOR coordinates protein synthesis, 




86.  Weinberg SE, Chandel NS. Targeting mitochondria metabolism for cancer 
therapy. Nat Chem Biol. 2015;11(1):9-15. doi:10.1038/nchembio.1712 
 
 
87.  Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Galluzzi L. Mitochondrial 
metabolism and cancer. Cell Res. 2018;28(3):265-280. doi:10.1038/cr.2017.155 
 
 
88.  Guerra F, Arbini AA, Moro L. Mitochondria and cancer chemoresistance. Biochim 
Biophys Acta BBA - Bioenerg. 2017;1858(8):686-699. doi:10.1016/j.bbabio.2017.01.012 
 
 
89.  Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse Effects of Cancer 
Chemotherapy: Anything New to Improve Tolerance and Reduce Sequelae? Front 
Pharmacol. 2018;9:245. doi:10.3389/fphar.2018.00245 
 
 
90.  Otto C, Kaemmerer U, Illert B, et al. Growth of human gastric cancer cells in 
nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and 
medium-chain triglycerides. BMC Cancer. 2008;8(1):122. doi:10.1186/1471-2407-8-122 
 
 
91.  Lashinger LM, Rossi EL, Hursting SD. Obesity and Resistance to Cancer 
Chemotherapy: Interacting Roles of Inflammation and Metabolic Dysregulation. Clin 
Pharmacol Ther. 2014;96(4):458-463. doi:10.1038/clpt.2014.136 
 
 
92.  Xie Y, Wang J-L, Ji M, et al. Regulation of insulin-like growth factor signaling by 




93.  Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, 
a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced 
nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada 





94.  Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, et al. The anti-malarial 
chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in 
HER2-positive breast cancer. Sci Rep. 2013;3:2469. doi:10.1038/srep02469 
 
95.  Chen S, Zhu X, Qiao H, et al. Protective autophagy promotes the resistance of 
HER2-positive breast cancer cells to lapatinib. Tumour Biol J Int Soc 
Oncodevelopmental Biol Med. 2016;37(2):2321-2331. doi:10.1007/s13277-015-3800-9 
 
 
96.  Dayyani F, Parikh NU, Varkaris AS, et al. Combined Inhibition of IGF-1R/IR and 
Src family kinases enhances antitumor effects in prostate cancer by decreasing 




97.  Grimaldi A, Balestrieri ML, D’Onofrio N, et al. The synergistic effect of everolimus 
and chloroquine on endothelial cell number reduction is paralleled by increased 




98.  Vidi P-A, Bissell MJ, Lelièvre SA. Three-Dimensional Culture of Human Breast 
Epithelial Cells: The How and the Why. In: Randell SH, Fulcher ML, eds. Epithelial Cell 




99.  Kapałczyńska M, Kolenda T, Przybyła W, et al. 2D and 3D cell cultures - a 




100.  Riedl A, Schlederer M, Pudelko K, et al. Comparison of cancer cells in 2D vs 3D 
culture reveals differences in AKT–mTOR–S6K signaling and drug responses. J Cell 
Sci. 2017;130(1):203-218. doi:10.1242/jcs.188102 
 
 
